Clinical Trial Update: A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants [Phase 1]

View source ↗

Summary

Phase 1 trial update for DX-2930 in hereditary angioedema assessing safety, tolerability, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• DX-2930

Snippet

Sponsor: Shire | Conditions: Hereditary Angioedema (HAE) | Phase 1 | Status: COMPLETED | Results posted: 2016-08-01